AU2022228660A1 - Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives - Google Patents

Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives Download PDF

Info

Publication number
AU2022228660A1
AU2022228660A1 AU2022228660A AU2022228660A AU2022228660A1 AU 2022228660 A1 AU2022228660 A1 AU 2022228660A1 AU 2022228660 A AU2022228660 A AU 2022228660A AU 2022228660 A AU2022228660 A AU 2022228660A AU 2022228660 A1 AU2022228660 A1 AU 2022228660A1
Authority
AU
Australia
Prior art keywords
triazol
hydroxymethyl
pyran
methyl
methoxytetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022228660A
Other languages
English (en)
Inventor
Martin Bolli
John Gatfield
Corinna Grisostomi
Lubos Remen
Christoph SAGER
Cornelia Zumbrunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AU2022228660A1 publication Critical patent/AU2022228660A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2022228660A 2021-03-03 2022-03-02 Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives Pending AU2022228660A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2021/055348 2021-03-03
EP2021055348 2021-03-03
PCT/EP2022/055224 WO2022184755A1 (en) 2021-03-03 2022-03-02 Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Publications (1)

Publication Number Publication Date
AU2022228660A1 true AU2022228660A1 (en) 2023-10-19

Family

ID=80682779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022228660A Pending AU2022228660A1 (en) 2021-03-03 2022-03-02 Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Country Status (20)

Country Link
US (1) US20240109930A1 (https=)
EP (1) EP4301748B1 (https=)
JP (1) JP7771205B2 (https=)
KR (1) KR20230154221A (https=)
CN (1) CN116888113A (https=)
AU (1) AU2022228660A1 (https=)
BR (1) BR112023017624A2 (https=)
CA (1) CA3209917A1 (https=)
CL (1) CL2023002578A1 (https=)
ES (1) ES3033422T3 (https=)
HR (1) HRP20250833T1 (https=)
HU (1) HUE072194T2 (https=)
IL (1) IL305581A (https=)
MA (1) MA63589B1 (https=)
MX (1) MX2023010241A (https=)
PL (1) PL4301748T3 (https=)
RS (1) RS67032B1 (https=)
TW (1) TWI905393B (https=)
UA (1) UA130562C2 (https=)
WO (1) WO2022184755A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
US12312362B2 (en) 2020-10-06 2025-05-27 Idorsia Pharmaceuticals Ltd Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en) 2020-11-02 2023-09-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
CN104755088A (zh) 2012-10-31 2015-07-01 格莱克特生物技术公司 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
EP3621973A4 (en) 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF
KR20200015528A (ko) 2017-05-12 2020-02-12 갈랙틴 사이언시즈, 엘엘씨 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
WO2019067702A1 (en) * 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
CA3080128A1 (en) 2017-10-31 2019-05-09 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2020104335A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US12269819B2 (en) * 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
WO2021004940A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
CN114206893A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物

Also Published As

Publication number Publication date
CA3209917A1 (en) 2022-09-09
PL4301748T3 (pl) 2025-09-08
WO2022184755A1 (en) 2022-09-09
TW202300146A (zh) 2023-01-01
TWI905393B (zh) 2025-11-21
MA63589B1 (fr) 2025-07-31
EP4301748A1 (en) 2024-01-10
HRP20250833T1 (hr) 2025-09-12
MX2023010241A (es) 2023-09-12
CL2023002578A1 (es) 2024-03-22
CN116888113A (zh) 2023-10-13
US20240109930A1 (en) 2024-04-04
EP4301748B1 (en) 2025-05-07
UA130562C2 (uk) 2026-03-18
JP2024509421A (ja) 2024-03-01
IL305581A (en) 2023-10-01
BR112023017624A2 (pt) 2023-10-10
EP4301748C0 (en) 2025-05-07
RS67032B1 (sr) 2025-08-29
JP7771205B2 (ja) 2025-11-17
KR20230154221A (ko) 2023-11-07
HUE072194T2 (hu) 2025-10-28
ES3033422T3 (en) 2025-08-04

Similar Documents

Publication Publication Date Title
EP4301748B1 (en) Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives
KR102863667B1 (ko) (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
EP4225752B1 (en) Spiro derivatives of alpha-d-galactopyranosides
EP4291556B1 (en) Hydroxyheterocycloalkane-carbamoyl derivatives
US12291520B2 (en) Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives
WO2021028336A1 (en) (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives
HK40103132A (en) Triazolyl‑methyl substituted alpha‑d‑galactopyranoside derivatives
HK40103132B (en) Triazolyl‑methyl substituted alpha‑d‑galactopyranoside derivatives
EA049121B1 (ru) Триазолил-метил-замещенные альфа-d-галактопиранозидные производные
HK40097240A (en) Spiro derivatives of alpha-d-galactopyranosides
HK40097240B (en) Spiro derivatives of alpha-d-galactopyranosides
HK40101885B (en) Hydroxyheterocycloalkane-carbamoyl derivatives
HK40101885A (en) Hydroxyheterocycloalkane-carbamoyl derivatives
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные